Disc Medicine (IRON) Cash from Financing Activities (2020 - 2026)

Disc Medicine (IRON) has 7 years of Cash from Financing Activities data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 99.31% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $230.9 million (down 48.32% YoY) and the FY2025 annual result came in at $473.4 million, up 116.85% from the prior year.
• Cash from Financing Activities eased to $1.7 million in Q1 2026 per IRON's latest filing, from $216.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $244.3 million in Q1 2025 and bottomed at $22000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is $11.6 million (2025), against an average of $63.6 million.
• The widest annual swing landed in 2022, when Cash from Financing Activities plunged 99.97%; it then surged 178801.16% in 2023.
• Tracing IRON's Cash from Financing Activities over 5 years: stood at $148.8 million in 2022, then plunged by 94.79% to $7.8 million in 2023, then surged by 271.19% to $28.8 million in 2024, then jumped by 652.43% to $216.7 million in 2025, then plunged by 99.22% to $1.7 million in 2026.
• Per Business Quant, the three latest IRON Cash from Financing Activities figures stand at $1.7 million (Q1 2026), $216.7 million (Q4 2025), and $11.6 million (Q3 2025).

Peer Comparison